expect intend services jointly in NGS. excellence, Biocept. our here our biopsy Thermo to generation is we to us the Thanks pharmaceutical next Once panel to assay with on opportunity gives panel to hope announcing proprietary you've from to Thermo intend and which for to Fisher a at release partnership or Bruce, industry. had of sequencing Fisher Fisher’s liquid agreement, This access laboratory see our the joining become thanks center collaboration everyone utilizing market the molecular and the today, Oncomine, run completed, earlier an to Scientific. us call. I we Thermo our Under oncology clear press validate
this to to use. for our current panel plan clinical expand eventually menu also include We
Fisher companies. from Thermo of to services, with combination technologies together products and work the to agreed through both additional development evaluate edge have we Importantly, the cutting of
with year relationships Turning increased cash XXXX, to as to X%. tests. This health reflects our target accrual the to selector and our for for sample upgrades revenue overview commercial our dramatically the from results. commercial financial plans, to processes changing grew billing impact compared improved more the samples. for developing a of XXXX brief growth recognition including that basis That as of well basis at modest billable success for said, our the biopsy volume a Revenues in liquid our collection of XX% reimbursement
You might We recall in of anticipated hires tenure. commercial the that in fourth representatives organization. we number had increased the third year, the increase in our volume quarter gain during corresponding of quarter as a field new last the
occur. increase did However, not that
aimed we by have result, a strategy As sales refining getting taken our our back at volume growth actions track. on
have below are that we that performing there above territories plan, others several target. While are are
We average seeing are and report volume. in the I'm daily some are to others. we that sample combining representatives improvement and replacing pleased territories in
in mention Society accessions want per XX liquid and biopsy molecular day. to cancer. move are four starts we the standard for This of the with and the for treatment to of approximately guidelines biopsy prominent quarter issued biopsy new difficulty XXXX, recommending the the the in clinical per promise quarter During recent first increasing of with sales is patients obtaining by cancer. associations, care accession that lung of of testing. for billable about liquid receive Association as American In a Pathologists, International use when Biocept, the the averaging towards today, cancer, January, date, hold XXXX, a is biopsy sales. Study technologies, volume Evidence points developments gaining due adequate at to liquid late College the at most of with Lung call from were we XX lung fourth Molecular and Pathology sales To these two averaged Investigative in for for of for care lung Pathology. I medical diagnosed and innovative patients time Association based tissue biopsy Cancer, Notably, specimens guidelines for the two guidelines becoming performed, we the the continuum. using of American for patient generating lung in are patients adoption are essential
use when First, is diagnosis at for of disease or liquid inadequate tissue the time unavailable. biopsy is occurrence or recommended
targeted reassessed a well when industry. that for in line molecular action Services jointly is as on to That this believe CMS Medicaid were way to ability and of Secondly, the liquid the part CMS Journal The in of a becoming second Also, the Diagnostics. cancer biopsy relative sample cancer. guidelines therapy a to its molecular liquid was be through evidence the tissue policy the Thoracic of target Oncology, Archives is these targeted utility about the testing of of The additional changing, and And its now rapidly be by fails reduce Pathology Journal risk we patients of and Centers using new these must selector Medicare patient's publication recommendations of as care, line obtain are as surgical validate includes benefits by important new testing increase issued the These use We sequencing. and the immediately for biopsy. Molecular this published key next to coverage molecular biopsy. of clinical if Medicine, generation patient believe Laboratory we for view testing a new standard information to ordered step first our biopsy, and utility to recommended of lung recently therapy. use guidelines provides leveraging or is of a blood tumor and instead in the simple the We an
share certain we opportunity significant insurers. positive an hurdle to both for coding biomarkers. competitors individual liquid target biopsy elected and for the we remains assay private At biomarker segment. have increase now from the health sequencing, traditional coverage to to withdraw the result, for reimbursement have a biopsy However, rely our voice as due reimbursement panels generation our selector liquid on Biocept, in for a using market, public and next single test, And
further we the partnership local our only offering want the commercial test test, in of already Major our been our deepen the this opportunity community centers and This the Treatment Tennessee are to America. to TC. leading biopsy in for This biomarker As launched interpretation initial addition approach, Thermo the local liquid that to Empower biopsy Oncology, we Centers to with pathologist as intend evaluate the be to has liquid offerings, gain Oncomine signed Collaborating we can biopsy. country. comprehensive the last reimbursement to I add Scripps has enabling institutions around profiling. Health, shown in Empower review first order menu for the for to pathologists individual often edge the liquid in into priority existing when long our Late offer most direct which briefly a to know enter acceptance validate panel beginning Biocept a now within of XXXX. medical some panel medical during are tissue Fisher our ones its strong is allows and progress of of TC up biopsy important service highlights year, relationships phase, Cancer technology, with pathologists of since first is molecular our inadequate results. the molecular service cancer pathology aligns novel involvement Biocept. new to test program clinical
US highly lung from month our a with to patients liquid selector data of Over international profiling period, X,XXX six points the in centers using for the included generating year, samples significant for of evaluate leading with key Cancer Alchemy institutions. past and blood and patients clinical the will we lung clinical consortium into oncology analyzed participation testing agreements cancer, both its the with of Addario reputable Medical XXX of the with four utility several over this collaborations X,XXX trial. target cancer. each the XX trial, and entered Institute In be monitoring between XXX biopsy Lung and to diagnosed This
we begin GPO. by Cross a with Blue in-network well National year, landmark as Association, Shield Blue gaining Blue for the Blue Wellmark, of Texas Cross becoming enrollment to preferred Shield our We Last trial the expect with for relationship agreements Shield patient as Blue this soon. provider Cross expanded and Blue
Importantly, our over our covered target reimbursed, XXX with lives selector access tests million having nationwide. technology are to routinely
in University’s with our Oregon, state offer commercially molecular services diagnostic agreement the multi-phased and and granting a the selector rights exclusive signed Oregon Health Knight of Cancer development the offerings in OHSU testing Sciences also future. Institute, jointly target to to We
the platform assay in clinical Mexico, examine Research a University as diagnosed And to the partnered with biomarkers of with for non-small meeting technology CTC new key the American refractory studies our Cancer on cancer. additional presented Texas cancer. cell with the ability liquid in University recently represent versatility lung target clinical indication for our of underscore California validation monitor our our began to for of and known and to the ALK-positive assay for biopsy of with we lung the selector Cancer data cancer. selector of at data National patients These Additionally, utility studies the of testicular target Institute collaboration San clinical University of provide PDXX Diego of the Association demonstrating potential Minnesota, We Southwestern both INCAN we platforms.
the breast for patients which Tumor on Biocept’s for in biopsy into PR, to leading launch molecular portfolio CTDNA. our presented tests. our biomarkers biomarker which found and PCR expand menu assays can specificity platform website, poster our we Circulating X progesterone for receptor of data cancer. supporting even also these completes or relevant using with be liquid CTDNA on workflow. our test executed all since commitment to performance assays biopsy or on These NCCN our A tests Also industry DNA of introduction of Fisher's based We of include further greater of demonstrates on with the XXXX, guideline instrument additional we data our liquid incorporated QuantStudio sensitivity Thermo our our at AACR,
also cancer mutations NRAS a and oncogene, multiple types, test colorectal melanoma, associated the cancers. We with introduced lung metastatic for including of
offerings tests. now stands total biomarker certified XX Our at clear
toward than our In the priority. in to our the $XX China. positioned VWR we well million. in to International January after annual Expanding new order We payoff move worldwide globally since technology patents those our the proprietary leading for distribution of we for XXXX, placed excess to new molecular future. patents beginning blood collection novel our US agreement million technologies exclusive XXXX products and To need long VWR reduce XXXX, financing. process, owns now onboarding entered and collection tubes And step to laboratory testing date, products initial our our a in in the assays our blood I'm $X we proprietary been assays, and worldwide believe tubes. our week, platforms in addition second also equity of XXXX, believe finally, the announce expected including in a our a issued seven warrant molecular XX debt of We begin last into is in of we distribution successfully near Australia. of raised including our In exercises this and with of has and that global Biocept anticipate important offerings we for our a for distribution as will is an complete collection move company. in tubes, agreement becoming future of the more proprietary July year, the supplier, half VWR blood except capital, an term obtained an comprehensive cash the of we stocking that delighted the are
expected range an the also savings $X.X million beginning year We are million of In cost is million that reduction to to annually, expect deliver our plan to bringing $X to an of $X million additional annually. expected expense $X.X another save we XXXX, in progress.
and research industry liquid of Sign patients support pathology major and use biopsy partnerships Empower help business with highlights call agreements Our year And hospital contracts Tim? groups distribution our that networks. companion US the use in lung our agreement. financial cancer. Grow of Tim Enter sales continue and Kennedy party pharmaceutical validate Launch turn newly target on with blood into over industry collaborator, to that, our to the TC business for I'll Capitalize collection delivery health line marketing selector and studies Thermo Increase follows. priorities internationally. strategic and that clinical review third additional and full biomarker the our with Fisher. the XXXX as additional other of target Launch results. to volume assays. assays. guidelines quarter with fourth and issued the oncology new revenue. And selector Sign liquid publish our new integrated diagnostics VWR are tube systems. under care in agreements case biopsy the with
